These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

947 related items for PubMed ID: 20870030

  • 1. Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis.
    Novitzky N, Thomas V, du Toit C, McDonald A.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):875-84. PubMed ID: 20870030
    [Abstract] [Full Text] [Related]

  • 2. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 3. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 5. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.
    Biol Blood Marrow Transplant; 2009 Jan 01; 15(1):30-8. PubMed ID: 19135940
    [Abstract] [Full Text] [Related]

  • 7. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.
    Jung AS, Holman PR, Castro JE, Carrier EK, Bashey A, Lane TA, Nelson CL, Pu M, Messer K, Corringham SM, Ball ED.
    Biol Blood Marrow Transplant; 2009 Oct 01; 15(10):1306-13. PubMed ID: 19747639
    [Abstract] [Full Text] [Related]

  • 8. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N, Thomas V, du Toit C.
    Cytotherapy; 2008 Oct 01; 10(1):45-53. PubMed ID: 18202974
    [Abstract] [Full Text] [Related]

  • 9. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK.
    Zhonghua Zhong Liu Za Zhi; 2006 Jul 01; 28(7):545-8. PubMed ID: 17147125
    [Abstract] [Full Text] [Related]

  • 10. Autologous stem cell transplantation in acute myeloid leukemia. Factors influencing outcome. A 13 year single institution experience.
    Martins C, Lacerda JF, Lourenço F, Carmo JA, Lacerda JM.
    Acta Med Port; 2005 Jul 01; 18(5):329-37. PubMed ID: 16611537
    [Abstract] [Full Text] [Related]

  • 11. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, Durrant S, Schwarer A, Bardy P, Herrmann R, Dodds A.
    Biol Blood Marrow Transplant; 2007 May 01; 13(5):601-7. PubMed ID: 17448920
    [Abstract] [Full Text] [Related]

  • 12. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
    Martino R, Caballero MD, de la Serna J, Díez-Martín JL, Urbano-Ispízua A, Tomás JF, Odriozola J, León A, Canals C, San Miguel J, Sierra J.
    Bone Marrow Transplant; 2002 Jul 01; 30(2):63-8. PubMed ID: 12132043
    [Abstract] [Full Text] [Related]

  • 13. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr 01; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 14. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K.
    Bone Marrow Transplant; 2005 May 01; 35(10):965-70. PubMed ID: 15806131
    [Abstract] [Full Text] [Related]

  • 15. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF, Fan ZP, Zhang Y, Jiang ZJ, Wang CY, Xu D, Sun J, Xiao Y, Tan H.
    Biol Blood Marrow Transplant; 2009 Nov 01; 15(11):1376-85. PubMed ID: 19822296
    [Abstract] [Full Text] [Related]

  • 16. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H, Ozdemir E, Uz B, Buyukasik Y, Turgut M, Serefhanoglu S, Aksu S, Sayinalp N, Haznedaroglu IC, Tekin F, Karacan Y, Unal S, Eliacik E, Isik A, Ozcebe OI.
    Transfus Apher Sci; 2013 Dec 01; 49(3):590-9. PubMed ID: 23981652
    [Abstract] [Full Text] [Related]

  • 17. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.
    Bone Marrow Transplant; 2001 Oct 01; 28(7):643-7. PubMed ID: 11704786
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

  • 19. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
    Wang HH, Feng SZ, Wang M, Wei JL, Jiang EL, Zhang L, Huang Y, Zhou SY, Liu QG, Qiu LG, Han MZ, Yan WW.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul 01; 25(7):389-92. PubMed ID: 15355688
    [Abstract] [Full Text] [Related]

  • 20. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
    McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S.
    J Clin Oncol; 2010 Apr 10; 28(11):1878-87. PubMed ID: 20212255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.